600587 新华医疗
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,528,5393.68%10,011,8689,281,7699,482,1999,150,960
减:营业总成本2,298,9063.74%9,238,9908,682,1248,934,8738,706,161
    其中:营业成本1,904,4285.83%7,271,3066,827,7797,182,6557,020,901
               财务费用4,405-47.32%14,40336,62963,652121,757
               资产减值损失1,489-139.24%(47,478)(51,846)(20,973)(88,420)
公允价值变动收益----12,536(43,356)61,123(171)
投资收益18,62468.85%81,11849,726112,22851,289
    其中:对联营企业和合营企业的投资收益13,14611.28%74,33262,10520,22832,236
营业利润238,345-2.83%756,953585,833720,186364,819
利润总额240,0051.65%738,579576,094718,029345,300
减:所得税费用24,981-26.69%62,07849,179162,005105,899
净利润215,0246.43%676,501526,914556,024239,401
减:非控股权益3,987-27.78%22,50426,842(470)5,262
股东净利润211,0377.39%653,997500,072556,494234,139

市场价值指针
每股收益 (元) *0.450-2.17%1.4301.2301.3700.580
每股派息 (元) *----0.5000.1500.1500.100
每股净资产 (元) *16.1519.63%15.68213.09112.09210.788
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容